Reviewing the body's immune response to a foreign substance is helpful to comprehend the
origin of an infusion reaction. Essentially, the administration of any foreign drug is likely to …

Background: Patients with cancer who are treated with monoclonal antibodies are at risk for
develo** infusion reactions. However, for some monoclonal antibodies, the incidence of …

Rituximab improved the prognosis of all B-cell derived lymphoproliferative diseases, but
despite 20 years of intensive use, it remains a drug with a number of still obscure …

Review of the Safety and Feasibility of Rapid Infusion of Rituximab - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …

The treatment of patients with rheumatoid arthritis (RA) has dramatically changed in the past
30 years. Currently, numerous conventional, biologic, and targeted synthetic DMARDs have …

Purpose Rituximab is a chimeric monoclonal antibody approved to treat B cell non-
Hodgkin's lymphoma (NHL). Infusion reactions among NHL patients are common during the …

Rituximab (Mabthera®) is currently approved for the treatment of multiple subtypes of CD20-
expressing, B-cell, non-Hodgkin's lymphoma. This study aimed to investigate whether rapid …

Lang DSP, Hagger C, Pearson A. International Journal of Nursing Practice 2011; 17: 357–
369 Safety of rapid rituximab infusion in adult cancer patients: A systematic review The …

Rituximab is an anti-CD20 monoclonal antibody often used in the treatment of rheumatoid
arthritis (RA). Infusion reactions sometimes develop following rituximab administration …

Patients with chronic inflammatory diseases such as rheumatoid arthritis have a higher risk
of cardiovascular diseases and related mortality compared to the general population. This …